Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Sunday May 17 2020, @04:17PM   Printer-friendly
from the getting-closer dept.

From the latest blog post of Derek Lowe :

One of the big (and so far unanswered) questions about the coronavirus epidemic is what kind of immunity people have after becoming infected. This is important for the idea of “re-infection” (is it even possible?) and of course for vaccine development. We’re getting more and more information in this area, though, and this new paper is a good example. A team from the La Jolla Institute for Immunology, UNC, UCSD, and Mt. Sinai (NY) reports details about the T cells of people who have recovered from the virus.

[...] So overall, this paper makes the prospects for a vaccine look good: there is indeed a robust response by the adaptive immune system, to several coronavirus proteins. And vaccine developers will want to think about adding in some of the other antigens mentioned in this paper, in addition to the Spike antigens that have been the focus thus far. It seems fair to say, though, that the first wave of vaccines will likely be Spike-o-centric, and later vaccines might have these other antigens included in the mix. But it also seems that Spike-protein-targeted vaccines should be pretty effective, so that’s good. The other good news is that this team looked for the signs of an antibody-dependent-enhancement response, which would be bad news, and did not find evidence of it in the recovering patients (I didn’t go into these details, but wanted to mention that finding, which is quite reassuring). And it also looks like the prospects for (reasonably) lasting immunity after infection (or after vaccination) are good. This, from what I can see, is just the sort of response that you’d want to see for that to be the case. Clinical data will be the real decider on that, but there’s no reason so far to think that a person won’t have such immunity if they fit this profile.

Onward from here, then – there will be more studies like this coming, but this is a good, solid look into the human immunology of this outbreak. And so far, so good.

Be sure to read the article if you’ve been wondering what your thymus has done for you lately.

Journal Reference
Alba Grifoni, Daniela Weiskopf. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell (DOI: 10.1016/j.cell.2020.05.015)


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 3, Informative) by PocketSizeSUn on Monday May 18 2020, @12:28AM (1 child)

    by PocketSizeSUn (5340) on Monday May 18 2020, @12:28AM (#995533)

    Yes .. I actually read the whole study which you obviously did not.

    The vaccine achieved seropositive results (that's good) but also cause liver disease (that's bad).
    The level of seropositive achieved is believed to be 'enough' but was below the level of seropositive of people who had SARS and survived (this is not atypical of a vaccine).
    So this vaccine may work but you have to get it in stages to get enough immunity to maintain any realistic possibility of protection from SARS.

    Also the trial size 36 healthy adults. That means that even 1 case of liver disease => 3% chance, 2 => 6% chance.
    Any sane person would RTFA (run-the-*-away) from this one.

    Starting Score:    1  point
    Moderation   +1  
       Insightful=1, Informative=1, Overrated=1, Total=3
    Extra 'Informative' Modifier   0  
    Karma-Bonus Modifier   +1  

    Total Score:   3  
  • (Score: 2) by NickM on Monday May 18 2020, @01:00AM

    by NickM (2867) Subscriber Badge on Monday May 18 2020, @01:00AM (#995548) Journal
    A transient increase in serum ALT is not that relevant in this study, again you selectivly choose not to state that it also occured in the placebo control group (1/12)...
    --
    I a master of typographic, grammatical and miscellaneous errors !